Overview

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

Status:
RECRUITING

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial, on healthy volunteers, is to learn more about safety and reactogenicity of the CD40.RBDv vaccine. The main questions that will be studied are : * Is the CD40.RBDv (adjuvanted or not) safe ? * Does the CD40.RBDv (adjuvanted or not) imply an immunologic response ? Participants will receive, depending on their randomization arm, 1 or 2 injections of the CD40.RBDv vaccine or a single injection of approved mRNA vaccine

Phase:

PHASE1

Details

Lead Sponsor:

ANRS, Emerging Infectious Diseases

Collaborators:

EnnoDc (previously known as LinKinVax)
Vaccine Research Institute (VRI), France

Treatments:

CVnCoV COVID-19 vaccine